Robert Dufour

8.9k total citations · 4 hit papers
115 papers, 5.0k citations indexed

About

Robert Dufour is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert Dufour has authored 115 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Surgery, 20 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert Dufour's work include Lipoproteins and Cardiovascular Health (52 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Cancer, Lipids, and Metabolism (13 papers). Robert Dufour is often cited by papers focused on Lipoproteins and Cardiovascular Health (52 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Cancer, Lipids, and Metabolism (13 papers). Robert Dufour collaborates with scholars based in Canada, United States and France. Robert Dufour's co-authors include Judith F. Kroll, Daniel Gaudet, Alexis Baass, Evan A. Stein, Traci Turner, Robert Pordy, John J.P. Kastelein, Martine Paquette, Jean Davignon and Gisle Langslet and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Robert Dufour

107 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

2017 738 citations Lawrence A. Leiter, Robert Dufour et al. profile →
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

2014 562 citations Frederick J. Raal, Evan A. Stein et al. The Lancet profile →
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

2012 463 citations Evan A. Stein, Daniel Gaudet et al. The Lancet profile →
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

2015 418 citations John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal profile →

Peers

Countries citing papers authored by Robert Dufour

Since Specialization

Citations

This map shows the geographic impact of Robert Dufour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dufour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dufour more than expected).

Fields of papers citing papers by Robert Dufour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dufour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dufour. The network helps show where Robert Dufour may publish in the future.

Co-authorship network of co-authors of Robert Dufour

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dufour. A scholar is included among the top collaborators of Robert Dufour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dufour. Robert Dufour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer 2024 ·Urologic Oncology Seminars and Original Investigations ·Mark Preston, Ramin Ebrahimi, (unknown), (unknown), Raj Desai, Mei Sheng Duh, (unknown), Sarah Hanson, Robert Dufour, Alicia K. Morgans	2
2	Treatment Patterns in Patients with Uterine Fibroids With and Without a Diagnosis of Heavy Menstrual Bleeding: Results from a Large U.S. Claims Database 2022 ·Journal of Women s Health ·(unknown), (unknown), Robert Dufour, (unknown)	5
3	PCN194 Prevalence of Major Adverse Cardiac Events (MACE) in Patients with Prostate Cancer (PC) Receiving Androgen Deprivation Therapy (ADT) in the United States 2020 ·Value in Health ·(unknown), (unknown), (unknown), David van Veenhuyzen, Robert Dufour	0
4	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry 2018 ·Atherosclerosis ·Liam R. Brunham, Isabelle L. Ruel, Étienne Khoury, Robert A. Hegele, Patrick Couture, Jean Bergeron, Alexis Baass, Robert Dufour, Gordon A. Francis, Lubomira Cermakova, G.B. John Mancini, James M. Brophy, (unknown), Daniel Gaudet, Jacques Genest	22
5	Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women 2017 ·Journal of Nutrition ·Hanny Wassef, (unknown), Robert Dufour, Jean Davignon, May Faraj	5
6	Myotoxicity of statins: Mechanism of action 2017 ·Pharmacology & Therapeutics ·Patrick du Souich, Ghislaine O. Roederer, Robert Dufour	117
7	The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia 2016 ·Journal of clinical lipidology ·Martine Paquette, Robert Dufour, Alexis Baass	66
8	A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia 2016 ·Journal of clinical lipidology ·Martine Paquette, Robert Dufour, Robert A. Hegele, Alexis Baass	8
9	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia breakdown → 2015 ·European Heart Journal ·John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet, G. Kees Hovingh, R Češka, Robert Dufour, Dirk Blom, Fernando Civeira, Michel Krempf, Christelle Lorenzato, Jian Zhao, Robert Pordy, Marie T. Baccara‐Dinet, Daniel A. Gipe, Mary Jane Geiger, Michel Farnier	418
10	PCSK9 Inhibition With Evolocumab (AMG 145) in Heterozygous Familial Hypercholesterolemia (RUTHERFORD-2): A Randomised, Double-Blind, Placebo-Controlled Trial 2015 ·Journal of Vascular Surgery ·Frederick J. Raal, Evan A. Stein, Robert Dufour	5
11	Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk 2015 ·Journal of clinical lipidology ·Yascara Grisel Luna Saavedra, Robert Dufour, Alexis Baass	43
12	The effect of insulin on circulating PCSK9 in postmenopausal obese women 2014 ·Clinical Biochemistry ·Zuhier Awan, Geneviève Dubuc, May Faraj, Robert Dufour, Nabil G. Seidah, Jean Davignon, Rémi Rabasa‐Lhoret, Alexis Baass	47
13	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial breakdown → 2014 ·The Lancet ·Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders Olsson, David Sullivan, G. Kees Hovingh, Bertrand Cariou, Ioanna Gouni‐Berthold, Ransi Somaratne, Ian Bridges, Robert C. Scott, Scott M. Wasserman, Daniel Gaudet	562
14	Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database 2014 ·Journal of Managed Care Pharmacy ·A Howe, (unknown), Robert Dufour, Neel Shah, David J. Harrison	44
15	HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study 2014 ·Molecular Psychiatry ·Valérie Leduc, Louis De Beaumont, Louise Théroux, Doris Dea, Paul Aisen, Ronald C. Petersen, (unknown), Robert Dufour, Judes Poirier	48
16	Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing? 2013 ·Canadian Journal of Cardiology ·Hwee Teoh, Jean‐Pierre Després, Robert Dufour, David Fitchett, (unknown), Shaun G. Goodman, Stewart B. Harris, Anatoly Langer, David C.W. Lau, Eva Lonn, G.B. John Mancini, Philip A. McFarlane, Paul Poirier, Rémi Rabasa‐Lhoret, Mary Tan, Lawrence A. Leiter	14
17	Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443) 2012 ·Circulation ·Robert Dufour, Patrick M. Moriarty, Elisabeth Genestin, William J. Sasiela, Yunling Du, (unknown), Henry N. Ginsberg	2
18	Abstract 19931: Mipomersen, An Apolipoprotein B Synthesis Inhibitor, Reduces Small LDL Particle Number and Increases LDL Particle Size in Patients with Heterozygous Familial Hypercholestrolemia and Coronary Artery Disease 2010 ·Circulation ·William C. Cromwell, Robert Dufour, Claude Gagné, Daniel Gaudet, Cara East, Joanne M. Donovan, Wai Chin, Diane L. Tribble, Mary P. McGowan	2
19	Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype 2009 ·Atherosclerosis ·Alexis Baass, Hanny Wassef, (unknown), Lise Bernier, Robert Dufour, Jean Davignon	12
20	Sécurisation des souches de crevettes d’élevage en Nouvelle-Calédonie. Résultats de la quarantaine et du conservatoire expérimental. Eléments pour la définition d’une stratégie de sécurisation des souches de crevettes en Nouvelle-Calédonie 2007 ·Institutional Archive of Ifremer (French Research Institute for Exploitation of the Sea) ·(unknown), E. Goyard, (unknown), Robert Dufour, Dominique Ansquer	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact